Clinical trials
RSV clinical trials
Below are recruiting rsv clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT07860216RecruitingPhase 3
RSV vaccine safety and immune response study for older adults
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
GuiZhou, GuizhouAges 60 years+ - NCT07768345RecruitingPhase 3
Revaccination with RSV vaccine for immunocompromised adults
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Los Angeles, CaliforniaAges 18 years+ - NCT07764237RecruitingPhase 1
mRNA vaccine for older adults to prevent RSV and hMPV
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Québec, QuebecAges 60 years+ - NCT07694557RecruitingPhase 1
Safety and immune response study of YKYY025 RSV vaccine
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Anning, YunnanAges 18 years+ - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT07653100RecruitingPhase 3
RSV vaccine study for adults with chronic conditions
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Visakhapatnam, Andhra PradeshAges 18 years+ - NCT07653347Recruiting
Infant RSV immunity study
Researchers want to study how infants naturally fight RSV infections. You and your baby may join if your baby is born in April, May, June, September, October, or November at BC Women's Hospital or a nearby hospital.
Vancouver, British ColumbiaAges Up to 6 months - NCT07640581Recruiting
RSV Infection Study in Babies Under 2 Years
This study tracks how respiratory syncytial virus (RSV)—a common respiratory infection in babies—affects children under 24 months in Ho Chi Minh City. Researchers want to understand how often RSV happens, how severe it is, and how it impacts families, so they can better prepare healthcare services.
Ho Chi Minh City, Ho Chi MinhAges birth–2 years - NCT07599449Recruiting
Tracking respiratory infections in French primary care
This study tracks viruses that cause sudden colds and flu-like illnesses during winter months in France. Researchers collect information from patients seen by participating doctors to better understand which respiratory viruses are circulating and help prepare for future outbreaks.
ParisAges Any age - NCT07601412Recruiting
Understanding Immune Response to Respiratory Viruses in Older Adults
This study examines how the body's natural defense system (specifically a type of immune protein) responds to common respiratory viruses like flu and cold in older adults. Researchers will analyze nasal samples that are already being collected as part of routine care to better understand why older people sometimes have different immune responses to these infections.
LyonAges 60 years+ - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT06775405RecruitingPhase 3
Testing a new RSV treatment for hospitalized babies
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
BeijingAges 1 month–2 years - NCT07460154Recruiting
Structured review to improve COPD management
This trial tests a structured review process to help people with COPD who have needed multiple steroid pills in the past year. It aims to improve care and prevent future harm from the condition.
North ShieldsAges 35 years+ - NCT07402512RecruitingPhase 3
Study of deuremidevir for RSV in infants and young children
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Xiamen, FujianAges 1 month–3 years - NCT06827249Recruiting
Testing peginterferon for RSV lung infection in young children
This trial tests a medication called peginterferon to treat RSV bronchiolitis (a lung infection causing wheezing and breathing trouble) in children ages 6 months to 2 years. It aims to see if the drug helps them recover faster.
Wuhan, HubeiAges 6 months–2 years - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT06856967Recruiting
Nirsevimab for RSV in infants under 1 year
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
Arezzo, ArezzoAges Up to 1 year - NCT06881056Recruiting
Aerosol interferon for RSV pneumonia in toddlers
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Chengdu, SichuanAges 1–3 - NCT07272434RecruitingPhase 3
RSV vaccine trial for adults 60 and older
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Guangzhou, GuangdongAges 60 years+ - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT07147517Recruiting
Tracking respiratory viruses in your community and home
This study tracks how respiratory viruses spread in the community and within households. It involves testing and collecting samples from people who are sick or healthy, to help better understand and prevent outbreaks.
La Jolla, CaliforniaAges Any age - NCT07106918RecruitingEarly Phase 1
SIBP-A16 Injection Safety Study in Healthy Adults
This study tests an experimental injection called SIBP-A16 in healthy adults to see if it is safe and how the body handles it. It helps researchers learn about the drug before testing it in people with a medical condition.
WuhanAges 18–45 - NCT06843317RecruitingPhase 1
RSV vaccine booster for older adults
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Phoenix, ArizonaAges 60–85
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rsv?
- Yes. Clin2 currently lists 59 recruiting rsv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rsv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rsv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.